232 related articles for article (PubMed ID: 15507476)
1. L-2-oxothiazolidine-4-carboxylic acid reduces in vitro cytotoxicity of glucose degradation products.
Breborowicz A; Witowski J; Polubinska A; Pyda M; Oreopoulos D
Nephrol Dial Transplant; 2004 Dec; 19(12):3005-11. PubMed ID: 15507476
[TBL] [Abstract][Full Text] [Related]
2. l-2-oxothiazolidine-4-carboxylic acid modulates function of peritoneal mesothelial cells in vitro.
Breborowicz A; Wisniewska J; Moberly JB; Oreopoulos DG
Am J Kidney Dis; 1999 Oct; 34(4):663-8. PubMed ID: 10516347
[TBL] [Abstract][Full Text] [Related]
3. Glucose-induced changes in the phenotype of human peritoneal mesothelial cells: effect of L-2-oxothiazolidine carboxylic acid.
Breborowicz A; Breborowicz M; Oreopoulos DG
Am J Nephrol; 2003; 23(6):471-6. PubMed ID: 14605496
[TBL] [Abstract][Full Text] [Related]
4. Time to reconsider saline as the ideal rinsing solution during abdominal surgery.
Połubinska A; Winckiewicz M; Staniszewski R; Breborowicz A; Oreopoulos DG
Am J Surg; 2006 Sep; 192(3):281-5. PubMed ID: 16920418
[TBL] [Abstract][Full Text] [Related]
5. Mesothelial toxicity of peritoneal dialysis fluids is related primarily to glucose degradation products, not to glucose per se.
Witowski J; Bender TO; Wisniewska-Elnur J; Ksiazek K; Passlick-Deetjen J; Breborowicz A; Jörres A
Perit Dial Int; 2003; 23(4):381-90. PubMed ID: 12968847
[TBL] [Abstract][Full Text] [Related]
6. Impact of low glucose degradation product bicarbonate/lactate-buffered dialysis solution on the epithelial-mesenchymal transition of peritoneum.
Oh EJ; Ryu HM; Choi SY; Yook JM; Kim CD; Park SH; Chung HY; Kim IS; Yu MA; Kang DH; Kim YL
Am J Nephrol; 2010; 31(1):58-67. PubMed ID: 19887789
[TBL] [Abstract][Full Text] [Related]
7. Effect of glucose degradation products on human peritoneal mesothelial cell function.
Witowski J; Korybalska K; Wisniewska J; Breborowicz A; Gahl GM; Frei U; Passlick-Deetjen J; Jörres A
J Am Soc Nephrol; 2000 Apr; 11(4):729-739. PubMed ID: 10752532
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products.
Lai KN; Leung JC; Chan LY; Li FF; Tang SC; Lam MF; Tse KC; Yip TP; Chan TM; Wieslander A; Vlassara H
Clin Exp Immunol; 2004 Dec; 138(3):466-75. PubMed ID: 15544624
[TBL] [Abstract][Full Text] [Related]
9. L-2-oxothiazolidine-4-carboxylate: an agent that modulates lipopolysaccharide-induced peritonitis in rats.
Korybalska K; Wieczorowska-Tobis K; Polubinska A; Wisniewska J; Moberly J; Martis L; Breborowicz A; Oreopoulos DG
Perit Dial Int; 2002; 22(3):293-300. PubMed ID: 12227385
[TBL] [Abstract][Full Text] [Related]
10. Effects of glutathione supplementation during peritoneal dialysis.
Styszynski A; Wieczorowska-Tobis K; Podkowka R; Breborowicz A; Oreopoulos DG
Adv Perit Dial; 2006; 22():88-93. PubMed ID: 16983947
[TBL] [Abstract][Full Text] [Related]
11. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells.
Witowski J; Korybalska K; Ksiazek K; Wisniewska-Elnur J; Jörres A; Lage C; Schaub TP; Passlick-Deetjen J; Breborowicz A; Grzegorzewska A; Ksiazek A; Liberek T; Lichodziejewska-Niemierko M; Majdan M; Rutkowski B; Stompór T; Sulowicz W
Nephrol Dial Transplant; 2004 Apr; 19(4):917-24. PubMed ID: 15031350
[TBL] [Abstract][Full Text] [Related]
12. Impact of 3,4-dideoxyglucosone-3-ene (3,4-DGE) on cytotoxicity of acidic heat-sterilized peritoneal dialysis fluid.
Tomo T; Okabe E; Yamamoto T; Namoto S; Iwashita T; Matsuyama K; Kadota J
J Artif Organs; 2007; 10(1):47-51. PubMed ID: 17380297
[TBL] [Abstract][Full Text] [Related]
13. Glucose degradation products (GDP) retard remesothelialization independently of D-glucose concentration.
Morgan LW; Wieslander A; Davies M; Horiuchi T; Ohta Y; Beavis MJ; Craig KJ; Williams JD; Topley N
Kidney Int; 2003 Nov; 64(5):1854-66. PubMed ID: 14531821
[TBL] [Abstract][Full Text] [Related]
14. The role of the glyoxalase pathway in reducing mesothelial toxicity of glucose degradation products.
Korybalska K; Wisniewska-Elnur J; Trómińska J; Jörres A; Breborowicz A; Witowski J
Perit Dial Int; 2006; 26(2):259-65. PubMed ID: 16623434
[TBL] [Abstract][Full Text] [Related]
15. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells.
Witowski J; Wisniewska J; Korybalska K; Bender TO; Breborowicz A; Gahl GM; Frei U; Passlick-Deetjen J; Jörres A
J Am Soc Nephrol; 2001 Nov; 12(11):2434-2441. PubMed ID: 11675420
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of viability of human peritoneal mesothelial cells with glutathione precursor: L-2-oxothiazolidine-4-carboxylate.
Breborowicz A; Witowski J; Martis L; Oreopoulos DG
Adv Perit Dial; 1993; 9():21-4. PubMed ID: 8105926
[TBL] [Abstract][Full Text] [Related]
17. The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products.
Boulanger E; Wautier MP; Gane P; Mariette C; Devuyst O; Wautier JL
Nephrol Dial Transplant; 2004 Sep; 19(9):2208-16. PubMed ID: 15213320
[TBL] [Abstract][Full Text] [Related]
18. Glucose degradation products and peritoneal membrane function.
Witowski J; Bender TO; Gahl GM; Frei U; Jörres A
Perit Dial Int; 2001; 21(2):201-5. PubMed ID: 11330569
[TBL] [Abstract][Full Text] [Related]
19. Newly Developed Neutralized pH Icodextrin Dialysis Fluid: Nonclinical Evaluation.
Yamaguchi N; Miyamoto K; Murata T; Ishikawa E; Horiuchi T
Artif Organs; 2016 Aug; 40(8):E158-66. PubMed ID: 27530675
[TBL] [Abstract][Full Text] [Related]
20. Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation.
Ha H; Yu MR; Choi HN; Cha MK; Kang HS; Kim MH; Lee HB
Perit Dial Int; 2000; 20 Suppl 5():S10-8. PubMed ID: 11229606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
